De Novo device
ArteraAI Prostate
Artera, Inc. · Pathology Software Algorithm Device Analyzing Digital Images For Prostate Cancer Prognosis (SFH, Class II) · First FDA decision Jul 31, 2025, newest Jul 31, 2025Prostate cancer
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
Breakthrough-designated
Device trials
0
Naming "ArteraAI"
MAUDE reports
0
Brand "ArteraAI", since 2015
PubMed studies
10
Mentioning "ArteraAI"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing ArteraAI Prostate
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- ArteraAI ProstateNew device typeBreakthroughDe Novo
DEN240068 · Decided Jul 31, 2025 · 248 days after receipt
Device type: Pathology Software Algorithm Device Analyzing Digital Images For Prostate Cancer Prognosis (SFH) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Autologous Cellular Immunotherapy Treatment of Metastatic Prostate CancerNational analysisReview closedCAG-00422NUpdated Nov 19, 2026
- Abarelix for the Treatment of Prostate CancerNational analysisReview closedCAG-00238NUpdated Sep 15, 2026
- Cryosurgical Salvage Therapy for Recurrent Prostate CancerNational analysisReview closedCAG-00064NUpdated Sep 14, 2026
- Cryosurgery Ablation for Prostate CancerNational analysisReview closedCAG-00031NUpdated Sep 14, 2026
- Codes That Are Not Covered by Medicare (Removal of ICD-9-CM Code V76.44, Prostate Cancer Screening, From the List)Coding analysisReview closedCAG-00297NUpdated Sep 14, 2026
- Prostate Cancer Screening TestsNational determinationOn the books210.1Updated Dec 11, 2024
- Prostate Cancer Detection with IsoPSA®Local determinationIn effectL39284CGS Administrators, LLCUpdated Oct 30, 2026
- MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized DiseaseLocal determinationIn effectL38303CGS Administrators, LLCUpdated Mar 10, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "ArteraAI", any status and sponsor, newest update first.
No registered device study names "ArteraAI".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "ArteraAI", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code SFH
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "ArteraAI"[tiab]. The summary above synthesizes these.
- Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.
Wang JH, Deek MP, Mendes AA, et al. · Radiother Oncol · 2025Multicenter Study, Validation Study
- Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.
Courtney PT, Shih YT, Chang AJ, et al. · JNCI Cancer Spectr · 2026
- External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol.
Parker CTA, Mendes L, Liu VYT, et al. · Lancet Digit Health · 2025Clinical Trial, Phase III, Multicenter Study
- Advancing Precision Oncology With Artificial Intelligence: Ushering in the ArteraAI Prostate Test.
Ghamande SS, Cline JK, Sayyid RK, et al. · Urology · 2024Editorial
- Harnessing Artificial Intelligence for Risk Stratification and Outcome Prediction in Urologic Cancers: A Systematic Review.
Roessler N, Miszczyk M, Miyajima K, et al. · Eur Urol Focus · 2025Review
- Optimal management of oligometastatic prostate cancer: current state and future directions.
Rooney MK, Corn PG, Tran PT · Curr Opin Oncol · 2026Review
- Multi-institutional Patient-level Comparison of Decipher Genomic Classifier and Artera Multimodal Artificial Intelligence (MMAI) in Prostate Cancer.
Hong BH, Olabumuyi AA, Zhao SG, et al. · Clin Cancer Res · 2026
- Clinical applications of artificial intelligence in genitourinary pathology.
Li A, Parwani A · Mol Aspects Med · 2026
- Biomarkers in prostate cancer: current status and future directions in radiotherapy-statement from the Prostate Cancer Working Group of the German Society of Radiation Oncology (DEGRO).
Spohn SKB, Aebersold DM, Albrecht C, et al. · Strahlenther Onkol · 2025Review, Research Support, Non-U.S. Gov't
- A multicentre implementation trial of an Artificial Intelligence-driven biomarker to inform Shared decisions for androgen deprivation therapy in men undergoing prostate radiotherapy: the ASTuTE protocol.
Wegener E, Ng M, Guerrieri M, et al. · BMC Cancer · 2025Clinical Trial Protocol
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.